Gilead Sciences Inc. (GILD) Price Targets: What Do They Mean?


As of Wednesday close, Gilead Sciences Inc.’s (NASDAQ:GILD) stock was up $0.19, moving up 0.22 percent to $85.42. The average number of shares traded per day over the past five days has been 6,284,480 shares. 4 times new highs have been achieved over the past 5 days, with a $2.54 gain in that time frame. In the last twenty days, the average volume was 9,543,680, while in the previous 50 days, it was 8,230,994.

Since last month, GILD stock rose 22.73%. Shares of the company fell to $68.09 on 10/24/22, the lowest level in the past month. A 52-week high of $86.15 was reached on 11/22/22 after having rallying from a 52-week low of $57.17. Since the beginning of this year, GILD’s stock price has risen by 17.64% or $12.81, and marked a new high 11 times. However, the stock has declined by -0.85% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


GILD stock investors should be aware that Gilead Sciences Inc. (GILD) stock had its last reported insider trading activity 16 days ago on Nov 09. Wilfong Diane E., the SVP, Controller & CAO of the company, disposed of 6,416 shares for $83.50 on Nov 09. It resulted in a $535,736 divestment by the insider. Wilfong Diane E. sold 16,255 shares at an average price of $79.25 on Nov 01. The insider now owns 28,333 shares following the transaction. On Mar 11, EVP,Corp Affairs & Gen Counsel Pletcher Brett A sold 3,634 shares at $58.24 apiece. The transaction was valued at $211,644.

Valuation Metrics

Right now, Gilead Sciences Inc. (GILD) has a P/E ratio of about 32.31. The stock’s beta is 0.45. Besides these, the trailing price-to-sales (P/S) ratio of 3.95, the price-to-book (PB) ratio of 5.08, and the price-to-cash flow ratio of 20.14 may also be considered.

The latest dividend of $0.73 per share was paid out, remained unchanged from last year’s $0.73. On Tuesday February 1 2022, a $0.02 dividend increase was announced.

Financial Health

In the three months ended September 29, Gilead Sciences Inc.’s quick ratio stood at 1.20, while its current ratio was 1.30, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 1.09, and the total debt-to-equity ratio was 1.20. On the profitability front, the trailing twelve-month gross margin is 74.60% percent. In the year ended September 29, operating margins totaled 22.10%. Based on annual data, GILD earned $20.7 billion in gross profit and brought in $27.3 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 16.40%. Return on equity (ROE) for the past 12 months was 16.20%.

In Gilead Sciences Inc.’s quarter-end financial report for September 29, it reported total debt of $22.95 billion against cash and short-term investments of $961.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. GILD’s revenue fell -5.38% to $6.26 billion during the quarter, while net income inched up to $7.04 billion. While analysts expected Gilead Sciences Inc. to report $1.43 quarterly earnings, the actual figure was $1.9 per share, beating the consensus estimate by 32.90%. During the quarter, the company generated $3.36 billion in EBITDA. The liabilities of Gilead Sciences Inc. were 41.5 billion at the end of its most recent quarter ended September 29, and its total debt was $26.22 billion. The value of shareholders’ equity is $1.25 billion.

Technical Picture

This quick technical analysis looks at Gilead Sciences Inc.’s (GILD) price momentum. With a historical volatility rate of 10.05%, the RSI 9-day stood at 85.32% on 23 November.

With respect to its five-day moving average, the current Gilead Sciences Inc. price is up by +3.06% percent or $2.54. At present, GILD shares trade +20.62% above its 20-day simple moving average and +37.02% percent above its 100-day simple moving average. However, the stock is currently trading approximately +31.05% above its SMA50 and +34.10% above its SMA200.

Stochastic coefficient K was 90.04% and Stochastic coefficient D was 90.78%, while ATR was 1.79. Given the Stochastic reading of 90.59% for the 14-day period, the RSI (14) reading has been calculated as 81.78%. As of today, the MACD Oscillator reading stands at 1.36, while the 14-day reading stands at 2.02.

Analyst Ratings

Barclays upgraded its rating on Gilead Sciences Inc. (NASDAQ: GILD) to an Equal weight in a note to investors on October 31, 2022. The analysts firm previously had an Underweight rating on the stock.Gilead Sciences Inc. (GILD) has been rated Overweight by analysts. According to 0 brokerage firms, GILD is a sell, and 17 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Gilead Sciences Inc. stock as buy, with 13 recommending it as overweight.

With a median target price of $83.00, the current consensus forecast for the stock is $63.00 – $96.00. Based on these forecasts, analysts predict Gilead Sciences Inc. (GILD) will achieve an average price target of $81.47.


Please enter your comment!
Please enter your name here